Addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. This title discusses new anticoagulants including oral Xa inhibitors, oral IIa inhibitors, and use of low molecular weight heparin to improve survival in cancer patients.